GlassScriptPhysician profile
Shannon Maeser
NPI 1427804608
$3,523.43
in general payments reported to CMS, 2019-2025
22 companies · $2,947 in 2025
The $2,947 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $576 · 2025: $2,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.49 |
| Education | $232.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noctrix Health, INC. | $2,400.83 | 2025 | Nidra |
| Inspire Medical Systems, INC. | $178.83 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $177.91 | 2024 | Airsupra, Farxiga |
| Harmony Biosciences LLC | $175.24 | 2025 | |
| Jazz Pharmaceuticals INC. | $132.95 | 2025 | |
| Abbvie INC. | $63.45 | 2024 | |
| Medtronic, INC. | $48.22 | 2024 | Kyphon Express II Kyphopak Tray |
| Eisai INC. | $41.07 | 2024 | |
| Amgen INC. | $35.70 | 2024 | Otezla, Repatha, Prolia |
| Exact Sciences Corporation | $30.85 | 2024 | Cologuard Collection Kit |
| Alkermes, INC. | $28.62 | 2024 | Vivitrol |
| Avadel Cns Pharmaceuticals, LLC | $28.13 | 2025 | Lumryz |
| Astellas Pharma US INC | $27.21 | 2024 | Veozah |
| Boston Scientific Corporation | $25.85 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.54 | 2024 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.40 | 2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $15.81 | 2025 | Zepbound |
| 3b Medical, INC. | $15.34 | 2025 | Luna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.97 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $14.21 | 2024 | |
| Aimmune Therapeutics, INC. | $14.07 | 2024 | |
| Glaxosmithkline, LLC. | $13.23 | 2024 | Trelegy Ellipta, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Maeser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.